Nahuel A García

Title: Innovator Nahuel A García: Pioneering Cardiotoxicity Prediction in Cancer Treatment

Introduction

Nahuel A García is a notable inventor based in Valencia, Spain. He has made significant contributions to the field of oncology, particularly in predicting cardiotoxicity risk in cancer patients undergoing anthracycline chemotherapy. His innovative approach aims to enhance patient safety and treatment efficacy.

Latest Patents

García holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also proposes a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.

Career Highlights

Throughout his career, Nahuel A García has worked with esteemed institutions such as the Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana and Maastricht University. His work has focused on improving cancer treatment outcomes and patient care.

Collaborations

García has collaborated with notable professionals in his field, including Jort Merken and Florian Caiment. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Nahuel A García's contributions to predicting cardiotoxicity in cancer patients represent a significant advancement in medical research. His innovative methods have the potential to improve treatment safety and patient outcomes in oncology.